SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
SpringWorks Therapeutics (Nasdaq: SWTX) announced participation in the 12th Annual Wedbush PacGrow Healthcare Conference on August 11, 2021, at 9:45 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SpringWorks Therapeutics (Nasdaq: SWTX) announced participation in the 12th Annual Wedbush PacGrow Healthcare Conference on August 11, 2021, at 9:45 AM ET. The management will engage in a Fireside Chat discussing the company's innovative approach to developing medicines for severe rare diseases and cancer. Interested parties can access the live webcast through the Investors & Media section of the company's website. SpringWorks is advancing 15 development programs, focusing on targeted oncology and has entered into multiple strategic partnerships to enhance its portfolio.
Details
News Market Reaction – SWTX
The recorded move for SWTX in the trading session of this news was +0.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STAMFORD, Conn., Aug. 03, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the 12th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 9:45AM ET.
To access the live webcast please visit the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing 15 development programs, including two potentially registrational clinical trials in rare tumor types as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to expand its portfolio to create more solutions for patients with cancer. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.
Contact:
Kim Diamond
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.